The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States
Bibliographic Data
| ID | 9103954 |
|---|---|
| Authors | Bruce R Schackman (0000-0002-1132-2932, Cornell University, corresponding author), Kelly A Gebo (0000-0003-4010-398X, Johns Hopkins University), Rochelle P Walensky (0000-0002-8795-379X, Brigham and Women's Hospital), Elena Losina (0000-0002-3424-0892, Boston University), Tammy Muccio, Tammy M Muccio (Harvard University), Paul E Sax (0000-0001-8434-174X, Brigham and Women's Hospital), Milton C Weinstein (Harvard University), George R Seage (0000-0001-5657-2970, Harvard University), Richard D Moore (0000-0001-8250-5069, Johns Hopkins University), Kenneth A Freedberg (0000-0001-6471-7930, Boston University) |
| Year | 2006 |
| Volume | 44 |
| Issue | 11 |
| Pages | 990-997 |
| Publication date | 2006-11-01 |
| Peer Reviewed | Yes |
| Open Access | No |
| Type | ARTICLE |
| Venue | Medical Care (JOURNAL) |
| Journal identifiers | ISSN: 0025-7079 • E-ISSN: 1537-1948 |
| Publisher | Ovid Technologies (Wolters Kluwer Health) (PUBLISHER) |
| DOI | 10.1097/01.mlr.0000228021.89490.2a |
| PMID | 17063130 |
| OpenAlex | W2090669065 |
| Language | EN |
| Citations received | 45 |
| References cited | 29 |
OBJECTIVE: We sought to project the lifetime cost of medical care for human immunodefiency virus (HIV)-infected adults using current antiretroviral therapy (ART) standards. METHODS: Medical visits and hospitalizations for any reason were from the HIV Research Network, a consortium of high-volume HIV primary care sites. HIV treatment drug regimen efficacies were from clinical guidelines and published sources; data on other drugs used were not available. In a computer simulation model, we projected HIV medical care costs in 2004 U.S. dollars. RESULTS: From the time of entering HIV care, per person projected life expectancy is 24.2 years, discounted lifetime cost is Dollars 385,200, and undiscounted cost is Dollars 618,900 for adults who initiate ART with CD4 cell count < 350/microL. Seventy-three percent of the cost is antiretroviral medications, 13% inpatient care, 9% outpatient care, and 5% other HIV-related medications and laboratory costs. For patients who initiate ART with CD4 cell count < 200/microL, projected life expectancy is 22.5 years, discounted lifetime cost is Dollars 354,100 and undiscounted cost is Dollars 567,000. Results are sensitive to drug manufacturers' discounts, ART efficacy, and use of enfuvirtide for salvage. If costs are discounted to the time of infection, the discounted lifetime cost is Dollars 303,100. CONCLUSIONS: Effective ART regimens have substantially improved survival and have increased the lifetime cost of HIV-related medical care in the U.S
Cost estimate · Enfuvirtide · Environmental health · Family medicine · Human immunodeficiency virus (HIV) · Intensive care medicine · Life expectancy · Population · Regimen · Viral load · HIV-related health complications and treatments · HIV/AIDS drug development and treatment · HIV/AIDS Research and Interventions · Immunology · Internal Medicine · Medicine
Computerized stress management training for HIV+ women
Risky sexual behavior and substance use among adolescents
Increasing late diagnosis in HIV infection in South Korea
Hiv / Aids
The economic burden of child maltreatment in the United States and implications for prevention
Behavioral Interventions to Reduce HIV-related Sexual Risk Behavior
"I'm Not Going to Die from the Aids"
The end of Aids
The Rise of Valley Fever
Determinants of Direct Costs of HIV-1 Outpatient Care in Israel
When “Heightened” Means “Lessened”
Self-Silencing and Age as Risk Factors for Sexually Acquired HIV in Midlife and Older Women
Attitudes and Stereotypes Regarding Older Women and HIV Risk
Using information on ART costs and benefits to mobilise resources – comparing different methods and contexts
Unprotected Sex Among Heterosexually Active Homeless Men
Moving from Fact to Policy
Is the US Aids Drug Assistance Program Cost-effective
Cost and Threshold Analysis of an HIV/STI/Hepatitis Prevention Intervention for Young Men Leaving Prison
Cost-Utility Analysis of the Housing and Health Intervention for Homeless and Unstably Housed Persons Living with HIV
Cost-Effectiveness of Interventions to Prevent HIV and STDs Among Women
Condom Distribution in Jail to Prevent HIV Infection
Cost Analysis of Enhancing Linkages to HIV Care Following Jail
Economic Evaluation of Community-Based HIV Prevention Programs in Ontario
A Study of Financial Incentives to Reduce Plasma HIV RNA Among Patients in Care
Cost and Threshold Analysis of Housing as an HIV Prevention Intervention
Cost and Threshold Analysis of Positive Charge, a Multi-site Linkage to HIV Care Program in the United States
Implementation of the Medicare Part D Prescription Drug Benefit is Associated with Antiretroviral Therapy Interruptions
Rates of Testing for HIV in the Presence of Serodiscordant UAI Among HIV-Negative Gay Men in Committed Relationships
Even If You Build It, We May Not Come
A benefit-cost framework for early intervention to prevent sex trading
Impact and cost-effectiveness analysis of the national school-based sexuality education programme in Estonia
Factors associated with risk for unprotected receptive and insertive anal intercourse in men aged 40 and older who have sex with men
Barriers and facilitators to HIV testing and linkage to primary care
Social-cognitive correlates of antiretroviral therapy adherence among HIV-infected individuals receiving infectious disease care in a medium-sized northeastern US city
Injection risk behaviors among rural drug users
Costs of care for people living with combined HIV/Aids, chronic mental illness, and substance abuse disorders
HIV economic burden of illness in the Veterans Health Administration population
Common elements in self-management of HIV and other chronic illnesses
Modeling the impact of a supervised consumption site on HIV and HCV transmission among people who inject drugs in three counties in California, USA
Direct treatment costs of HIV/Aids in Portugal
The Lifetime Medical Cost Savings From Preventing HIV in the United States
Determining the Cost-Savings Threshold for HIV Adherence Intervention Studies for Persons with Serious Mental Illness and HIV
Sisters, Mothers, Daughters and Aunties”
The Cost and Intensity of Behavioral Interventions to Promote HIV Treatment for Prevention Among HIV-Positive Men Who Have Sex with Men
Costs of care provided in a university hospital for children exposed to or infected with the HIV/Aids
Cost-Effectiveness in Health and Medicine
Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
The Care of HIV-Infected Adults in the United States
A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
Lifetime medical costs for women
High Rates of Primary Mycobacterium avium Complex and Pneumocystis jiroveci Prophylaxis in the United States
| Unique citing works | 45 |
|---|---|
| Citations per year | 2,37 |
| Citation span | 2007 - 2024 (18) |
| Citation velocity | recent |
| Highly cited | No |
| Citation types | Neutral: 43 |